Research programme: Duchenne muscular dystrophy therapeutics - RASRx

Drug Profile

Research programme: Duchenne muscular dystrophy therapeutics - RASRx

Alternative Names: MMX 1902; RASRx 1902

Latest Information Update: 23 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator RASRx
  • Class
  • Mechanism of Action Angiotensin modulators; Renin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Duchenne muscular dystrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Duchenne muscular dystrophy

Most Recent Events

  • 15 Jun 2017 MMX 1902 receives Orphan Drug status for Duchenne muscular dystrophy in USA
  • 15 Jun 2017 RASRx plans clinical trials for Duchenne muscular dystrophy
  • 01 Mar 2017 Preclinical trials in Duchenne muscular dystrophy in USA (PO) before March 2017 (CureDuchenne pipeline, February 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top